Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (NASDAQ: LFCR) is described as a fully integrated contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products and injectable-grade hyaluronic acid. The Lifecore news feed on this page aggregates company-issued updates and related coverage so readers can follow how the business communicates its progress and key events over time.
News items commonly include financial results for specific reporting periods, where Lifecore discusses revenue trends across its CDMO and HA manufacturing activities, operational initiatives, and non-GAAP measures such as Adjusted EBITDA. The company also issues announcements about new CDMO agreements, including master services agreements and commercial site transfer arrangements with large multinational pharmaceutical companies, as well as development agreements with early-stage biotechnology customers.
In addition, Lifecore regularly reports on strategic collaborations and industry participation. Examples include a collaboration with PolyPeptide Laboratories, Inc. to support peptide-based pharmaceutical customers and participation in healthcare and investor conferences such as the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, and specialized pharmaceutical manufacturing events. These updates provide insight into how Lifecore presents its capabilities in formulation, fill/finish, and packaging of sterile injectables.
Other news may cover corporate and governance developments, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), index-related announcements like expected inclusion in the Nasdaq Biotechnology Index, and scheduling of earnings webcasts and investor presentations. Investors, analysts, and industry observers can use this page to track the company’s own descriptions of its growth strategy, operational improvements, and relationships with biopharmaceutical and biotechnology partners.
Lifecore Biomedical (NASDAQ: LFCR) will participate in DCAT Week 2026, March 23-26, 2026, in New York City. Lifecore's team will host customers and prospective partners to discuss development and manufacturing solutions for injectable programs. Meetings are available by contacting cdmo@lifecore.com.
Lifecore Biomedical (NASDAQ: LFCR) announced that on January 14, 2026 its compensation committee approved inducement equity grants for two newly hired employees under the company’s Equity Inducement Plan.
The grants consist of 1,738 restricted stock units (RSUs) and stock options covering an aggregate 8,775 shares. RSUs vest and settle on the third anniversary of the grant subject to continued employment. Options have an exercise price equal to Fair Market Value on the grant date, vest 1/3 after one year then 1/36 monthly thereafter, and expire after seven years.
Lifecore Biomedical (NASDAQ: LFCR) announced it will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI) as part of Nasdaq's annual index reconstitution. The inclusion is expected to be effective prior to market open on Monday, December 22, 2025.
The Nasdaq Biotechnology Index tracks Nasdaq-listed securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is calculated using a modified capitalization-weighted methodology. Constituents are selected once annually in December and must meet eligibility requirements including minimum market capitalization, average daily trading volume, and public company seasoning.
Lifecore Biomedical (NASDAQ: LFCR) signed a CDMO master services agreement on Dec 17, 2025 with a new large multinational pharmaceutical customer to provide development services and tech transfer for an injectable pharmaceutical product.
The program contemplates transferring commercial supply from overseas to Lifecore facilities, and Lifecore expects to become the commercial supplier once transfer and regulatory requirements are satisfied. Based on current commercial revenues for the program, the partner could become one of Lifecore’s top five commercial customers. This is Lifecore’s second multinational agreement in the past three months.
Lifecore Biomedical (NASDAQ: LFCR) said it will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.
Company management, including Paul Josephs (chief executive officer) and Ryan Lake (chief financial officer), are scheduled to participate in 1-on-1 meetings during the conference.
Lifecore Biomedical (NASDAQ: LFCR) will participate in two investor conferences in November 2025: the Jefferies 2025 Global Healthcare Conference in London and the Stephens Annual Investment Conference in Nashville. Paul Josephs, president and CEO, will deliver a corporate presentation and take part in investor meetings at Jefferies on Nov 18, 2025 at 9:30 a.m. GMT (4:30 a.m. ET) and will be a featured fireside chat speaker at Stephens on Nov 20, 2025 at 9:00 a.m. CT. Management will hold 1-on-1 meetings across both events (Nov 17–20 and Nov 18–20 respectively). Webcasts of both sessions will be available live and as replays via Lifecore’s Investor Events & Presentations page at https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR) reported revenue of $31.1 million for the three months ended September 30, 2025, a 26% increase versus the comparable prior period, and recorded a net loss of $10.0 million (loss per diluted share $0.29).
Gross profit rose to $7.8 million. Adjusted EBITDA improved to $3.1 million from negative $1.8 million a year earlier. SG&A expense declined by $5.9 million. Interest expense increased to $6.3 million, partly due to Alcon term loan PIK interest and debt discount amortization.
The company signed multiple new programs, improved manufacturing productivity by 20%+, plans an ERP go-live in Q1 2026, and affirmed transition-period guidance of revenue $74–76M, net loss $16.4–18.4M, and Adjusted EBITDA $12–14M.
Lifecore Biomedical (NASDAQ: LFCR) will report financial results for the three months ended September 30, 2025 on Thursday, November 6, 2025 after market close.
Management will host a live webcast at 4:30 p.m. Eastern Time the same day to discuss results. To listen live or access the archived webcast (available for 30 days), visit the company’s Investor Events & Presentations page: https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR) announced on October 29, 2025 that it signed an agreement to execute a commercial site transfer and become the commercial supplier of choice for a leading injectable pharmaceutical product after regulatory requirements are satisfied. This is the second agreement with the same multinational customer in recent months. Lifecore also signed a separate pre-clinical formulation development agreement with an early-stage biotech, expanding its early-stage pipeline.
The deals are positioned to increase capacity utilization, broaden the commercial customer base, and leverage Lifecore’s fill-finish and regulatory track record as a U.S.-based CDMO for sterile injectables.
Lifecore Biomedical (NASDAQ: LFCR) and PolyPeptide announced a collaboration on October 28, 2025 to deliver an integrated end-to-end peptide manufacturing solution for the U.S. market.
The agreement pairs PolyPeptide’s peptide drug substance (DS) development and manufacturing capabilities with Lifecore’s formulation, fill/finish, and packaging expertise to enable a seamless DS-to-drug product (DP) transition, with the stated goals of accelerating development timelines, lowering development costs and risks, and providing a fully U.S.-based supply chain with aligned regulatory oversight.